Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Operating Expenses (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Operating Expenses for 5 consecutive years, with $22.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 3.73% year-over-year to $22.0 million, compared with a TTM value of $90.2 million through Dec 2025, down 3.15%, and an annual FY2025 reading of $90.2 million, down 3.15% over the prior year.
  • Operating Expenses was $22.0 million for Q4 2025 at Aligos Therapeutics, down from $29.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $38.3 million in Q4 2021 and bottomed at $19.5 million in Q2 2025.
  • Average Operating Expenses over 5 years is $26.6 million, with a median of $26.1 million recorded in 2022.
  • The sharpest move saw Operating Expenses tumbled 33.38% in 2022, then soared 35.99% in 2025.
  • Year by year, Operating Expenses stood at $38.3 million in 2021, then tumbled by 31.57% to $26.2 million in 2022, then rose by 9.38% to $28.7 million in 2023, then dropped by 26.1% to $21.2 million in 2024, then increased by 3.73% to $22.0 million in 2025.
  • Business Quant data shows Operating Expenses for ALGS at $22.0 million in Q4 2025, $29.1 million in Q3 2025, and $19.5 million in Q2 2025.